Apamistamab-B10-Astatine At-211
Myelodysplastic Syndrome With Excess Blasts
Explore 32 assets in Myelodysplastic Syndrome With Excess Blasts →Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
antibody_drug_conjugate
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03670966CT.gov 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myelodysplastic Syndrome With Excess Blasts
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Apamistamab-B10-Astatine At-211 (this asset) | Fred Hutchinson Cancer Center | P1/2 | CC · 47 |
| Cytarabine | University of Southern California | P3 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | BB |
| Tacrolimus | Fred Hutchinson Cancer Center | P2 | BB |
| Fludarabine | Fred Hutchinson Cancer Center | P3 | BB |
| Idarubicin | Fred Hutchinson Cancer Center | P3 | BB |
| Etoposide | M.D. Anderson Cancer Center | P3 | BB |
| Cyclophosphamide | Fred Hutchinson Cancer Center | P3 | BB |
| Dexasone | National Cancer Institute (NCI) | P3 | BB |
+42 more in the Myelodysplastic Syndrome With Excess Blasts cohort
Other indications for Apamistamab-B10-Astatine At-211
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | — | P1/2 | CCC · 48 |
| Acute Myeloid Leukemia | — | P1/2 | CCC · 48 |
| Mixed Phenotype Acute Leukemia | — | P1/2 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Apamistamab-B10-Astatine At-211 in Myelodysplastic Syndrome With Excess Blasts. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/apamistamab-b10-astatine-at-211-myelodysplastic-syndrome-with-excess-blasts
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →